Aarthi Jayanthan

Aarthi Jayanthan's Title

Aarthi Jayanthan serves as the Chief Operating Officer (COO), a pivotal role that involves overseeing the daily operations and strategic direction of the organization. Her comprehensive background in molecular cancer biology and clinical trial support equips her with the unique expertise needed to manage complex operational tasks and drive innovative projects forward. As a COO, Aarthi leverages her extensive research and development experience to optimize organizational efficiency and spearhead initiatives that align with the company's mission of advancing cancer therapies.

Aarthi Jayanthan's Education and Expertise

Aarthi Jayanthan earned her Ph.D. at the University of Calgary, specializing in molecular cancer biology and cell signaling. Her doctoral research focused on developing novel therapies for children with cancer, a testament to her dedication to pediatric oncology. Her academic journey has equipped her with a deep understanding of cancer biology, which she has applied to numerous preclinical studies and clinical trials. Aarthi's expertise extends to biomarker development, gene expression profiling, and drug resistance modeling, making her a respected figure in the field of cancer research.

Aarthi Jayanthan's Contributions to Cancer Research

Aarthi Jayanthan has made significant contributions to cancer research, particularly in the area of childhood cancer. She has been involved in preclinical studies of experimental therapies for various types of childhood cancers, including leukemia, AT/RT, neuroblastoma, and lymphoma. Aarthi has also supported Phase I clinical trials sponsored by the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC), helping to bring new treatments to the clinical stage. Her work has been instrumental in advancing the understanding of cancer biology and developing new therapeutic approaches.

Aarthi Jayanthan's Innovations in Biomarker Development

Aarthi Jayanthan has led groundbreaking work in biomarker development. She spearheaded the biomarker co-development of RSK2 CDxV, guiding it from pre-clinical method development to a CAP/CLIA certified clinical stage assay in collaboration with Roche Ventana. Additionally, she advanced several surrogate biomarker programs using gene expression profiling on the Nanostring platform. Aarthi also developed the first blood biomarker assay for RSK inhibitors, a significant milestone in cancer diagnostics. Her innovative work has paved the way for more precise and personalized cancer treatments.

Aarthi Jayanthan's Achievements in Drug Resistance and Combinations

Aarthi Jayanthan has achieved notable success in understanding and overcoming drug resistance in cancer therapy. She developed models of drug resistance for several breast cancer therapeutics, including paclitaxel and CDK4/6 inhibitors. Her research identified novel drug combinations for PMD-026, expanding the potential to maximize life-cycle development following initial regulatory approval. Aarthi's work in this area not only enhances the effectiveness of existing treatments but also opens new avenues for combination therapies, offering hope to patients with resistant cancer types.